{"title":"药品准入法:高药价的行政征用解决方案","authors":"Brittany S. Bruns","doi":"10.15779/Z38V97ZR9S","DOIUrl":null,"url":null,"abstract":"Introduction ........................................................................................... 2024 I. The Economics of Pharmaceutical Pricing in the United States: A Broken Market ........................................................................... 2028 II. Market Failure Examples: Hepatitis C Drugs, EpiPen, and Daraprim ................................................................................................... 2033 A. Gilead Sets High Prices for Patented Hepatitis C Treatments 2034 B. Mylan Gradually Aggressively Marketed EpiPens Before Hiking Prices ..................................................................... 2037 C. Turing Leveraged Regulatory Barriers to Increase Price of Daraprim ............................................................................ 2041 III. Current Regulatory Pressure ........................................................... 2044 A. Congressional Hearings ..................................................... 2044 B. Antitrust Laws ................................................................... 2044 C. Targeted Discount and Rebate Programs .......................... 2046 D. 28 U.S.C. § 1498 ................................................................ 2047 1. Problems with Section 1498: Disperse Decision-Making Leads to a Bystander Effect ......................................... 2050 2. Problems with Section 1498: Potential Misapplication to Optimally Incented Products Discourages Investment in Innovation .................................................................... 2050","PeriodicalId":51452,"journal":{"name":"California Law Review","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"The Pharmaceutical Access Act: An Administrative Eminent Domain Solution to High Drug Prices\",\"authors\":\"Brittany S. Bruns\",\"doi\":\"10.15779/Z38V97ZR9S\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction ........................................................................................... 2024 I. The Economics of Pharmaceutical Pricing in the United States: A Broken Market ........................................................................... 2028 II. Market Failure Examples: Hepatitis C Drugs, EpiPen, and Daraprim ................................................................................................... 2033 A. Gilead Sets High Prices for Patented Hepatitis C Treatments 2034 B. Mylan Gradually Aggressively Marketed EpiPens Before Hiking Prices ..................................................................... 2037 C. Turing Leveraged Regulatory Barriers to Increase Price of Daraprim ............................................................................ 2041 III. Current Regulatory Pressure ........................................................... 2044 A. Congressional Hearings ..................................................... 2044 B. Antitrust Laws ................................................................... 2044 C. Targeted Discount and Rebate Programs .......................... 2046 D. 28 U.S.C. § 1498 ................................................................ 2047 1. Problems with Section 1498: Disperse Decision-Making Leads to a Bystander Effect ......................................... 2050 2. Problems with Section 1498: Potential Misapplication to Optimally Incented Products Discourages Investment in Innovation .................................................................... 2050\",\"PeriodicalId\":51452,\"journal\":{\"name\":\"California Law Review\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2018-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"California Law Review\",\"FirstCategoryId\":\"90\",\"ListUrlMain\":\"https://doi.org/10.15779/Z38V97ZR9S\",\"RegionNum\":2,\"RegionCategory\":\"社会学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"LAW\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"California Law Review","FirstCategoryId":"90","ListUrlMain":"https://doi.org/10.15779/Z38V97ZR9S","RegionNum":2,"RegionCategory":"社会学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"LAW","Score":null,"Total":0}
引用次数: 1
摘要
介绍 ...........................................................................................2024 i在美国药品定价的经济学:破碎的市场 ...........................................................................2028二世。市场失灵的例子:丙型肝炎药物,EpiPen, Daraprim ...................................................................................................2033 A。基列集高价专利丙型肝炎治疗2034 b Mylan逐渐积极销售EpiPens徒步旅行之前的价格 .....................................................................2037 c图灵杠杆增加Daraprim价格监管障碍 ............................................................................2041 III。当前的监管压力 ...........................................................2044 A。国会听证会 .....................................................2044 b .反垄断法 ...................................................................2044 c .针对性的折扣和回扣计划 ..........................2046 d . 28事项§1498 ................................................................2047年1。1498年问题部分:分散决策导致了旁观者效应 .........................................2050 2。第1498节:问题潜在的滥用最佳鼓励产品阻碍了对创新的投资 ....................................................................2050
The Pharmaceutical Access Act: An Administrative Eminent Domain Solution to High Drug Prices
Introduction ........................................................................................... 2024 I. The Economics of Pharmaceutical Pricing in the United States: A Broken Market ........................................................................... 2028 II. Market Failure Examples: Hepatitis C Drugs, EpiPen, and Daraprim ................................................................................................... 2033 A. Gilead Sets High Prices for Patented Hepatitis C Treatments 2034 B. Mylan Gradually Aggressively Marketed EpiPens Before Hiking Prices ..................................................................... 2037 C. Turing Leveraged Regulatory Barriers to Increase Price of Daraprim ............................................................................ 2041 III. Current Regulatory Pressure ........................................................... 2044 A. Congressional Hearings ..................................................... 2044 B. Antitrust Laws ................................................................... 2044 C. Targeted Discount and Rebate Programs .......................... 2046 D. 28 U.S.C. § 1498 ................................................................ 2047 1. Problems with Section 1498: Disperse Decision-Making Leads to a Bystander Effect ......................................... 2050 2. Problems with Section 1498: Potential Misapplication to Optimally Incented Products Discourages Investment in Innovation .................................................................... 2050
期刊介绍：
This review essay considers the state of hybrid democracy in California through an examination of three worthy books: Daniel Weintraub, Party of One: Arnold Schwarzenegger and the Rise of the Independent Voter; Center for Governmental Studies, Democracy by Initiative: Shaping California"s Fourth Branch of Government (Second Edition), and Mark Baldassare and Cheryl Katz, The Coming of Age of Direct Democracy: California"s Recall and Beyond. The essay concludes that despite the hoopla about Governor Schwarzenegger as a "party of one" and a new age of "hybrid democracy" in California.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
